One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
Abdullah also attributed GSK’s willingness to go all-in on mo-rez on the leadership of Luke Miels, who stepped up as CEO of ...
With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its ...
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing ...
A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...
Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy ...
Hello, and welcome to this market update with the Swedish Diabetes Research Company, Diamyd Medical. On Friday evening, the company announced negative interim results from its Phase III study. We will ...
City launches new website for West Lake Drive Phase 3 with construction updates and project information for residents, city ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results